Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

ABSTRACT: In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer patients. Although antibody therapy has continuously been improved, still a significant number of patients do not benefit from antibody therapy. Therefore, rational optimization of the antibody molecule by Fc engineering represents a major area of translational research to further improve this potent therapeutic option. Monoclonal antibodies are able to trigger a variety of effector mechanisms. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement- dependent cytotoxicity (CDC) are considered important in antibody therapy of cancer. Novel mechanistic insights into the action of monoclonal an

SUBMITTER: Kellner C 

PROVIDER: S-EPMC5649276 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature